Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953995086> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2953995086 endingPage "S75" @default.
- W2953995086 startingPage "S75" @default.
- W2953995086 abstract "R/R-MCL is an incurable, aggressive B-cell lymphoma as most patients will relapse. While costs are unknown, median overall survival for salvage regimens post-ibrutinib is 5.8 months (Martin et al. 2016). We describe costs and HRU patterns for patients who fail ibrutinib. Using IQVIA claims, this analysis describes R/R-MCL patients failing prior chemotherapy, rituximab, and ibrutinib (using multi-step algorithm) between November 13, 2013 and August 31, 2017. Primary outcomes were treatment patterns, site-of-care costs and total cost pre/post-ibrutinib failure. Demographic, treatment patterns, and costs were analyzed descriptively. Median follow-up analyzed by Kaplan-Meier method. For the 64 R/R-MCL patients identified, median age was 63 (range 49-84) years and 72% were male. Pre-ibrutinib, patients received a median of 2 (range 1-5) regimens, including bendamustine (72%), R-CHOP (52%), and bortezomib (25%) with 22% receiving hematopoietic stem cell transplant (HSCT). Post-ibrutinib failure, 41% patients continued with salvage therapies and <1% received HSCT. Post-ibrutinib, a median of 2 (range 1-5) regimens were administered--including lenalidomide (35%), bortezomib (25%), and bendamustine (23%). Median per-patient-per-month healthcare costs pre-ibrutinib, during ibrutinib, and post ibrutinib treatment were $21,728 (range $1,730 - $78,631), $21,664 (range $6,335 - $505,675), and $24,103 (range $0 - $554,440), respectively. Drug costs were a major driver of healthcare costs pre- and during ibrutinib treatment, representing 46% and 73% of total costs, respectively. However, post-ibrutinib, hospital costs represented the greatest share (54%) of total costs. There was a trend in longer follow-up time in the group receiving subsequent therapies (p=0.06). There is no standard of care for R/R-MCL patients who fail ibrutinib. Most patients (59%) did not receive any subsequent therapy post-ibrutinib, demonstrating an unmet need for novel therapies. Those who did received less intensive, single-agent therapies. The healthcare costs for such patients remain high with inpatient costs being the largest contributor." @default.
- W2953995086 created "2019-07-12" @default.
- W2953995086 creator A5039349765 @default.
- W2953995086 creator A5065521448 @default.
- W2953995086 creator A5087366513 @default.
- W2953995086 date "2019-05-01" @default.
- W2953995086 modified "2023-09-27" @default.
- W2953995086 title "PCN103 REAL-WORLD COSTS AND HEALTHCARE RESOURCE UTILIZATION (HRU) PATTERNS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R-MCL) PATIENTS POST-IBRUTINIB FAILURE" @default.
- W2953995086 doi "https://doi.org/10.1016/j.jval.2019.04.227" @default.
- W2953995086 hasPublicationYear "2019" @default.
- W2953995086 type Work @default.
- W2953995086 sameAs 2953995086 @default.
- W2953995086 citedByCount "0" @default.
- W2953995086 crossrefType "journal-article" @default.
- W2953995086 hasAuthorship W2953995086A5039349765 @default.
- W2953995086 hasAuthorship W2953995086A5065521448 @default.
- W2953995086 hasAuthorship W2953995086A5087366513 @default.
- W2953995086 hasBestOaLocation W29539950861 @default.
- W2953995086 hasConcept C126322002 @default.
- W2953995086 hasConcept C143998085 @default.
- W2953995086 hasConcept C2776063141 @default.
- W2953995086 hasConcept C2776364478 @default.
- W2953995086 hasConcept C2776694085 @default.
- W2953995086 hasConcept C2777478702 @default.
- W2953995086 hasConcept C2777525834 @default.
- W2953995086 hasConcept C2777938653 @default.
- W2953995086 hasConcept C2778461978 @default.
- W2953995086 hasConcept C2779338263 @default.
- W2953995086 hasConcept C2779878957 @default.
- W2953995086 hasConcept C2780653079 @default.
- W2953995086 hasConcept C2780775027 @default.
- W2953995086 hasConcept C2781442060 @default.
- W2953995086 hasConcept C71924100 @default.
- W2953995086 hasConceptScore W2953995086C126322002 @default.
- W2953995086 hasConceptScore W2953995086C143998085 @default.
- W2953995086 hasConceptScore W2953995086C2776063141 @default.
- W2953995086 hasConceptScore W2953995086C2776364478 @default.
- W2953995086 hasConceptScore W2953995086C2776694085 @default.
- W2953995086 hasConceptScore W2953995086C2777478702 @default.
- W2953995086 hasConceptScore W2953995086C2777525834 @default.
- W2953995086 hasConceptScore W2953995086C2777938653 @default.
- W2953995086 hasConceptScore W2953995086C2778461978 @default.
- W2953995086 hasConceptScore W2953995086C2779338263 @default.
- W2953995086 hasConceptScore W2953995086C2779878957 @default.
- W2953995086 hasConceptScore W2953995086C2780653079 @default.
- W2953995086 hasConceptScore W2953995086C2780775027 @default.
- W2953995086 hasConceptScore W2953995086C2781442060 @default.
- W2953995086 hasConceptScore W2953995086C71924100 @default.
- W2953995086 hasLocation W29539950861 @default.
- W2953995086 hasOpenAccess W2953995086 @default.
- W2953995086 hasPrimaryLocation W29539950861 @default.
- W2953995086 hasRelatedWork W2145676206 @default.
- W2953995086 hasRelatedWork W2419585914 @default.
- W2953995086 hasRelatedWork W2777757127 @default.
- W2953995086 hasRelatedWork W2790959278 @default.
- W2953995086 hasRelatedWork W2954035736 @default.
- W2953995086 hasRelatedWork W2972330211 @default.
- W2953995086 hasRelatedWork W2982898843 @default.
- W2953995086 hasRelatedWork W3025062852 @default.
- W2953995086 hasRelatedWork W3035724450 @default.
- W2953995086 hasRelatedWork W4280556984 @default.
- W2953995086 hasVolume "22" @default.
- W2953995086 isParatext "false" @default.
- W2953995086 isRetracted "false" @default.
- W2953995086 magId "2953995086" @default.
- W2953995086 workType "article" @default.